ACADIA: Is It The Right Time To Buy?

  • Acadia stock has lagged behind the broad sector despite strong Nuplazid uptake.
  • The main investor concern is cash burn.
  • However, this is an overreaction.

By S. Mitra

The biotech sector is back with a bang. Reports that Washington might go soft on the whole drug pricing issue has propelled the iShares Biotech ETF (NASDAQ:IBB) to above $300 for the first time in 18 months. One promising biotech stock that seems to be missing out on the party though is ACADIA Pharmaceuticals (NASDAQ:ACAD).

The full post is available to investor members only. Subscribe here.